Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Revenue of Aprea Therapeutics, Inc. (APRE)
Revenue in 2023 (TTM): $583.23 K
According to Aprea Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $583.23 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Aprea Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $583.23 K | $576.18 K | $-15,464,910 | $-14,286,756 | $-14,286,756 |
| 2022 | $ | $-186,445 | $38.37 M | $-112,662,027 | $-224,875,387 |
| 2021 | $ | $-271,677 | $-37,763,755 | $-37,127,303 | $-36,536,576 |
| 2020 | $ | $-229,610 | $-51,920,960 | $-53,478,812 | $-53,916,802 |
| 2019 | $ | $-170,254 | $-30,872,438 | $-28,059,807 | $-26,405,062 |
| 2018 | $ | $-8,316 | $-16,481,087 | $-15,528,269 | $-15,528,269 |
| 2017 | $ | $-7,932 | $-16,506,583 | $-15,190,250 | $-15,190,250 |